Literature DB >> 8244156

Hormone replacement therapy in chronic active hepatitis; a case report.

D Clements1, J Rhodes.   

Abstract

There is an increased incidence of osteoporosis in patients with chronic liver disease. Because patients with chronic active hepatitis (CAH) usually require corticosteroids for their liver disease prevention and treatment of bone loss presents a difficult problem. This case report describes a 41 year old female patient with CAH who had a high rate of bone loss. After an early menopause with noticeable menopausal symptoms, she was given transdermal oestrogen replacement therapy. The menopausal symptoms resolved completely, and there was no deterioration in her liver function tests or corticosteroid requirement. In addition, follow up quantitative bone mineral measurements over two years have shown improvement. This case shows the value of measurements of bone density, and oestrogen replacement therapy in CAH, even in the presence of continued corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244156      PMCID: PMC1374440          DOI: 10.1136/gut.34.11.1639

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  Bone disease in liver transplant recipients: incidence, timing, and risk factors.

Authors:  M K Porayko; R H Wiesner; J E Hay; R A Krom; E R Dickson; S Beaver; L Schwerman
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

2.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.

Authors:  R D Soloway; W H Summerskill; A H Baggenstoss; M G Geall; G L Gitnićk; I R Elveback; L J Schoenfield
Journal:  Gastroenterology       Date:  1972-11       Impact factor: 22.682

3.  Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.

Authors:  G C Cook; R Mulligan; S Sherlock
Journal:  Q J Med       Date:  1971-04

4.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

5.  Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy.

Authors:  A J Stellon; A Davies; J Compston; R Williams
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

6.  Adjuvant oestrogen treatment increases bone mineral density in postmenopausal women with rheumatoid arthritis.

Authors:  H R van den Brink; W F Lems; A A van Everdingen; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1993-04       Impact factor: 19.103

7.  Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis.

Authors:  A P Kirk; S Jain; S Pocock; H C Thomas; S Sherlock
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

8.  Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss.

Authors:  B P Lukert; B E Johnson; R G Robinson
Journal:  J Bone Miner Res       Date:  1992-09       Impact factor: 6.741

9.  Bone loss after liver transplantation.

Authors:  J A McDonald; C R Dunstan; P Dilworth; K Sherbon; A G Sheil; R A Evans; G W McCaughan
Journal:  Hepatology       Date:  1991-10       Impact factor: 17.425

10.  Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease.

Authors:  D Clements; J E Compston; W D Evans; J Rhodes
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.